Compare IRDM & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRDM | PVLA |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2007 | N/A |
| Metric | IRDM | PVLA |
|---|---|---|
| Price | $24.73 | $140.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 17 |
| Target Price | $27.33 | ★ $154.59 |
| AVG Volume (30 Days) | ★ 2.1M | 332.9K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.50% | N/A |
| EPS Growth | ★ 12.77 | N/A |
| EPS | ★ 1.06 | N/A |
| Revenue | ★ $871,659,000.00 | N/A |
| Revenue This Year | $3.50 | N/A |
| Revenue Next Year | $2.26 | N/A |
| P/E Ratio | $22.60 | ★ N/A |
| Revenue Growth | ★ 4.93 | N/A |
| 52 Week Low | $15.65 | $18.23 |
| 52 Week High | $33.34 | $151.18 |
| Indicator | IRDM | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 62.64 | 71.46 |
| Support Level | $23.46 | $76.95 |
| Resistance Level | $24.98 | $151.18 |
| Average True Range (ATR) | 0.95 | 9.71 |
| MACD | -0.02 | 2.75 |
| Stochastic Oscillator | 93.15 | 84.79 |
Iridium Communications Inc is the commercial provider of communications services offering true globalised coverage, connecting people, organizations and assets to and from anywhere, in real time. The company is a provider of mobile voice and data communications services through a constellation of low earth-orbiting satellites. Iridium's solutions are ideally suited for industries such as maritime, aviation, government/military, emergency/humanitarian services, mining, forestry, oil and gas, heavy equipment, transportation, and utilities. Iridium also provides service to subscribers from the U.S. Department of Defense, as well as other civil and government agencies world-wide. The Company operates in one business segment, providing satellite communications services and products.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.